The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
"UK pharmaceutical firm Shire has struck a $32bn (£22bn) deal for US rival Baxalta" 2nd acquisition in a few months, Prices always take a tumble upon this sort of news doesn't it? Expect about another 10% drop before it even begins to level out.
Very very odd Price bounced around today, yet come end of day there were 3 trades, very odd, I've cashed out now as the volumes are less than appealing and I can only seeing the initial Mellon hype dying off.
I am basing it on this being a young share that currently has no news coming, with little chart data to use for evaluation, this and the fact the 1 day spike went up 1.5 to its high and dropped 1.5 the next, and has proceeded to creep from there.
They really need to do something about peoples buys showing as sells, if people rely on the sell / buy ratio of trades as defined it can skew people in to selling when all is rosy. Volume traded today was down about 70% from yesterday, hopefully we'll see good volumes tomorrow and a bit of a boost towards 4.5p. Good article, I feel 6p is a bit hopeful as it is such a short lived trend that I do not think it will expand at that rate for the coming months so, more around 5p I think is realistic, but even at 5p that's still a fair rise from where we are now.
That's amazing, only 34.77% of the company is in public hands As at 4th January 2016, shareholders holding more than 3% of the share capital of Tissue Regenix Group Plc are: Name of shareholder % of voting rights Invesco Limited 27.80 Woodford Investment Management LLP 15.72 Techtran Group Limited 13.56 Baillie Gifford & Co Ltd 4.86 University of Leeds 4.47 Jupiter Asset Management 4.45 NFU Mutual 3.79 John Samuel 3.19 Shares not in public hands as at 4th January 2016 – 495,866,863 - 65.23% Shares in issue as at 4th January 2016 - 760,124,264 ordinary shares of 0.5p each
Been reading up more on TRX product lines, they seem amazing, and they already have DermaPure established in the US so have a point on entry to a massive market for their other stuff. The fact they can strip a sequence from something so there's no possibility of rejection opens up a whole new world of possibility when it comes to transplants etc. This is definitely one to buy as a keeper, a proper slow burner at the moment but once products get approvals / releases this will easily hit +50% DYOR as always
Some big sellers today, last of the profit takers from the initial rise i'm guessing, meaning this can only go up. Melon will help this company grow big time. This should go past 4.5p tomorrow, if it manages to break past the 4.88 from close on 31st Dec then who knows where it'll end.